Literature DB >> 12724054

Are beta-blockers efficacious as first-line therapy for hypertension in the elderly?

Konrad Wink1.   

Abstract

The aim of this paper is to assess antihypertensive efficacy of b-blockers and their effects on cardiovascular morbidity and mortality and all-cause mortality in elderly patients with hypertension. Randomized placebo-controlled trials, trials with untreated controls, and trials comparing antihypertensive drugs were selected from the literature. The relative risk reduction of primary endpoints and 95% confidence intervals were calculated. There were six trials in which elderly patients were treated with beta-blockers for hypertension (three trials were placebo-controlled, one trial had untreated controls, and two trials compared antihypertensive drugs). There was no study with monotherapy of beta-blockers. In combination with diuretics, beta-blockers were superior to placebo and untreated controls in preventing cardiovascular events, especially strokes, but there was no superiority of beta-blockers to angiotensin-converting enzyme inhibitors and calcium antagonists in preventing cardiovascular morbidity and mortality and total mortality in elderly patients with hypertension. Beta-blockers are only efficacious in combination with diuretics in preventing cardiovascular morbidity and mortality in elderly patients with hypertension.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12724054     DOI: 10.1007/s11906-003-0024-y

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  8 in total

1.  Randomised trial of treatment of hypertension in elderly patients in primary care.

Authors:  J Coope; T S Warrender
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-01

2.  Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.

Authors:  L Hansson; L H Lindholm; T Ekbom; B Dahlöf; J Lanke; B Scherstén; P O Wester; T Hedner; U de Faire
Journal:  Lancet       Date:  1999-11-20       Impact factor: 79.321

3.  Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)

Authors:  B Dahlöf; L H Lindholm; L Hansson; B Scherstén; T Ekbom; P O Wester
Journal:  Lancet       Date:  1991-11-23       Impact factor: 79.321

4.  Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study.

Authors:  L Hansson; T Hedner; P Lund-Johansen; S E Kjeldsen; L H Lindholm; J O Syvertsen; J Lanke; U de Faire; B Dahlöf; B E Karlberg
Journal:  Lancet       Date:  2000-07-29       Impact factor: 79.321

5.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

6.  Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP).

Authors:  J B Kostis; K G Berge; B R Davis; C M Hawkins; J Probstfield
Journal:  Am J Hypertens       Date:  1995-12       Impact factor: 2.689

7.  Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review.

Authors:  F H Messerli; E Grossman; U Goldbourt
Journal:  JAMA       Date:  1998-06-17       Impact factor: 56.272

8.  Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party.

Authors: 
Journal:  BMJ       Date:  1992-02-15
  8 in total
  1 in total

Review 1.  Tocotrienol is a cardioprotective agent against ageing-associated cardiovascular disease and its associated morbidities.

Authors:  Nardev Ramanathan; Esther Tan; Li Jun Loh; Boon Seng Soh; Wei Ney Yap
Journal:  Nutr Metab (Lond)       Date:  2018-01-19       Impact factor: 4.169

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.